Global Biosimilars Market Outlook to 2026


Dublin, June 02, 2021 (GLOBE NEWSWIRE) – The “Biosimilars Market: Global Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2021-2026” the report was added to from offer.

The biosimilars market reached a value of US $ 7.7 billion in 2020. This market is currently influenced by a number of factors such as the expiration of successful biologic drug patents, falling prices, prevalence. growing chronic disease and government cost reduction initiatives. and third-party payers. Catalyzed by these factors, the market is expected to experience strong growth over the next five years.

Biosimilars, also known as follow-up biologics, refer to a biotherapeutic product that is very similar to a reference biologic drug. It is produced from living organisms or cells and has a complex molecular structure. When a biologic drug’s patent expires, manufacturers seek regulatory approval to start production of biosimilars. To be labeled as a biosimilar, a biologic drug must be proven similar in terms of quality, safety and efficacy. Compared to generic drugs, biosimilars are expensive because their production process is more complex and requires greater investment in research and development.

Drivers / constraints of the global biosimilars market:

  • Over the years, the patents for several successful biologic drugs have expired and a number of successful drugs are still expected to lose their patent protection in the years to come. This should provide huge opportunities for biosimilar manufacturers in the near future.
  • Cost-cutting initiatives undertaken by governments and third-party payers have encouraged the use of biosimilars over brand-name biologics, thereby propelling demand for biosimilars.
  • Other factors driving the demand for biosimilars include cost-effectiveness, the increasing prevalence of chronic diseases (such as autoimmune diseases and cancer), and the growing geriatric population.
  • There are some factors that are hampering the growth of the biosimilars market. This includes the negative perception of doctors, patent extensions, the lower price difference compared to small molecule generics, etc.

Key market segmentation:

This report provides an analysis of key trends within each sub-segment of the global Biosimilars market report, along with growth forecast at the global, regional, and country level from 2021 to 2026. Our report has categorized the market on the basis of region, information on molecules, information on indications and information on manufacturing.

Information on molecules:

On the basis of Molecule, the market has been segmented into Infliximab, Insulin Glargine, Epoetin Alfa, Etanercept, Filgrastim, Somatropin, Rituximab, Follitropin Alfa, etc. Currently, Infliximab dominates the market, holding the largest share.

Information on indications:

Based on the indication, autoimmune diseases account for the majority of the total market share. Other major indications include oncology, diabetes, blood disorders, growth retardation, female infertility, etc.

Manufacturing outlook:

Based on the type of manufacturing, the market is divided into in-house manufacturing and contract manufacturing. Of these, in-house manufacturing accounts for the majority of the market share.

Regional perspectives:

Regionally, the market has been segmented into United States, Germany, France, Italy, Spain, United Kingdom, Japan, India, South Korea, and others. .

Competitive landscape:

The competitive landscape of the global biosimilars market has also been analyzed. Some of the major players operating in the market are:

  • Novartis
  • Pfizer
  • Suits you
  • Celltrion
  • Merck & Co
  • Samsung Bioepis
  • Eli lilly
  • Biocon
  • Dr Reddy’s laboratories
  • Amgen
  • Boehringer Ingelheim

This report provides an in-depth overview of the global Biosimilars market covering all its essential aspects. It ranges from macro market overview to micro details of industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, ‘value chain analysis, etc. This report is must-read for entrepreneurs, investors, researchers, consultants, business strategists, and anyone with any interest in or planning to enter the biosimilars market in any way.

Main topics covered:

1 Preface

2 Scope and methodology

3 Executive summary

4 Biosimilars Market – Introduction
4.1 Overview
4.2 WHO and FDA terminology on biosimilars
4.3 Biosimilars and generics
4.4 Biosimilars and brand name biologics

5 Why are biosimilars so lucrative?
5.1 Patent expiration of successful biologic drugs
5.2 Significant price difference between biosimilars and innovative medicines
5.3 Savings for government and third-party payers
5.4 Growing prevalence of lifestyle-related diseases
5.5 Incentives for prescribers, pharmacists and patients
5.6 Emergence of new players in Europe and in emerging markets
5.7 Increased product differentiation as manufacturers partner with drug delivery device companies

6 Research, development and manufacture of biosimilars
6.1 Research and development: biosimilar medicines versus innovative medicines
6.2 Manufacturing: biosimilar drugs versus innovative drugs

7 Biosimilars market
7.1 Market overview
7.2 Historical performance
7.3 Impact of COVID-19
7.4 Market breakdown by segment
7.5 Market breakdown by type of manufacturer
7.6 Market breakdown by indication
7.7 Market breakdown by region
7.8 Market forecast
7.9 Biosimilar patent landscape
7.9.1 US Patent Landscape
7.9.2 Patent landscape in Europe
7.9.3 Patent landscape in Japan
7.10 SWOT analysis
7.10.1 Presentation
7.10.2 Strengths
7.10.3 Weaknesses
7.10.4 Opportunities
7.10.5 Threats
7.11 Value chain analysis
7.11.1 Characterization of the existing innovator drug
7.11.2 Research and development Characterization of biosimilars Development of a single cell line
7.11.3 Product development Pre-test Intermediate clinical tests (PK / PD) Confirmatory clinical phase III
7.11.4 Final product formulation
7.11.5 Marketing and distribution
7.12 Porter’s five forces analysis
7.12.1 Presentation
7.12.2 Bargaining power of buyers
7.12.3 Bargaining power of suppliers
7.12.4 Degree of competition
7.12.5 Threat of new entrants
7.12.6 Threat of substitutes
7.13 Price analysis
7.13.1 Key price indicators
7.13.2 Price trends
7.13.3 Analysis of margins

8 Market breakdown by molecule
8.1 Infliximab
8.2 Insulin Glargine
8.3 Epoetin Alfa
8.4 Etanercept
8.5 Filgrastim
8.6 Somatropin
8.7 Rituximab
8.8 Follitropin Alfa

9 Market breakdown by type of manufacturing
9.1 In-house manufacturing
9.1.1 Market trends
9.1.2 Market Forecast
9.2 Contract manufacturing
9.2.1 Market trends
9.2.2 Market Forecast

10 Market breakdown by indication
10.1 Autoimmune diseases
10.1.1 Market trends
10.1.2 Market Forecast
10.2 Blood disorder
10.2.1 Market trends
10.2.2 Market Forecast
10.3 Diabetes
10.3.1 Market trends
10.3.2 Market Forecast
10.4 Oncology
10.4.1 Market trends
10.4.2 Market Forecast
10.5 Growth deficit
10.5.1 Market trends
10.5.2 Market Forecast
10.6 Female infertility
10.6.1 Market trends
10.6.2 Market Forecast

11 Market breakdown by region
11.1 Europe
11.1.1 Market performance
11.1.2 Key players and biosimilars
11.1.3 Market breakdown by country
11.1.4 Market Forecast
11.1.5 Italy Market performance Key players and biosimilars Market Forecast
11.1.6 Germany Market performance Key players and biosimilars Market Forecast
11.1.7 France Market performance Key players and biosimilars Market Forecast
11.1.8 United Kingdom Market performance Key players and biosimilars Market Forecast
11.1.9 Spain Market performance Key players and biosimilars Market Forecast
11.1.10 Rest of Europe Market performance Market Forecast
11.2 United States
11.2.1 Current market trends
11.2.2 Key players and biosimilars
11.2.3 Market Forecast
11.3 Japan
11.3.1 Market performance
11.3.2 Key players and biosimilars
11.3.3 Market Forecast
11.4 India
11.4.1 Current market trends
11.4.2 Key players and biosimilars
11.4.3 Market Forecast
11.5 South Korea
11.5.1 Current Market Trends
11.5.2 Key players and biosimilars
11.5.3 Market Forecast
11.6 Rest of the world
11.6.1 Current Market Trends
11.6.2 Market Forecast

12 Requirements for setting up a biosimilar manufacturing plant
12.1 Manufacturing process
12.2 Raw material requirements
12.3 Raw material images
12.4 Land and construction requirements
12.5 Machinery and infrastructure requirements
12.6 Photos of machines
12.7 Plant layout
12.8 Packaging requirements
12.9 Utility requirements
12.10 Labor requirements

13 Competitive landscape
13.1 Market structure
13.2 Key players
13.3 Profiles of key players
13.3.1 Novartis
13.3.2 Pfizer
13.3.3 Teva
13.3.4 Celltrion
13.3.5 Merck & Co
13.3.6 Samsung Bioepis
13.3.7 Eli Lilly
13.3.8 Biocon
13.3.9 Amgen
13.3.10 Dr Reddy’s Laboratories
13.3.11 Boehringer Ingelheim

For more information on this report, visit


Source link

Leave A Reply

Your email address will not be published.